Voyager Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $124.12M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | During market hours | $3.20M | $-0.40 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | During market hours | $2.60M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 9, 2026 | During market hours | $15.30M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | Before market open | $13.40M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | During market hours | $5.20M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | During market hours | $6.50M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 11, 2025 | During market hours | $6.30M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | During market hours | $24.60M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | During market hours | – | – | – |
Press releases
Announcements Voyager Therapeutics filed with the SEC
Voyager Reports Second Quarter 2026 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Voyager Reports First Quarter 2026 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Leveraging Genetics to Treat Neurological Diseases Corporate Deck / January 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
I want to take a moment to share why 2026 is a pivotal year in Voyager’s
Regulation FD disclosure · EX-99.2 to Form 8-K
Voyager Reports Third Quarter 2025 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Leveraging Genetics to Treat Neurological Diseases Citi 2025 Biopharma Back to School Conference September 2, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Voyager Reports Second Quarter 2025 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Voyager Reports First Quarter 2025 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Voyager Reports Third Quarter 2024 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Voyager Therapeutics Announces Pricing of Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Voyager Therapeutics Announces Selection of
Other events · EX-99.1 to Form 8-K
Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K
Voyager Therapeutics Reports Third Quarter 2021 Financial and Operating Results
Results of operations · EX-99.1 to Form 8-K